Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott Sells 3,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott sold 3,000 shares of the company’s stock in a transaction on Thursday, April 25th. The stock was sold at an average price of $7.67, for a total transaction of $23,010.00. Following the transaction, the chief operating officer now directly owns 543,231 shares in the company, valued at $4,166,581.77. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Tina Marriott also recently made the following trade(s):

• On Thursday, March 21st, Tina Marriott sold 8,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.75, for a total transaction of $86,000.00.
• On Thursday, February 22nd, Tina Marriott sold 8,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $14.89, for a total transaction of $119,120.00.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock opened at $8.20 on Tuesday. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.54 and a 12-month high of $16.75. The stock has a market capitalization of $1.92 billion, a P/E ratio of -5.29 and a beta of 0.76. The firm’s 50-day moving average is $10.27 and its two-hundred day moving average is $9.16.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The company had revenue of $10.89 million for the quarter, compared to analysts’ expectations of $12.37 million. As a group, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. KeyCorp increased their price objective on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. TD Cowen assumed coverage on shares of Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a “market perform” rating on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $12.75.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth about $26,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Recursion Pharmaceuticals by 81.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 43,656 shares of the company’s stock worth $435,000 after acquiring an additional 19,565 shares during the period. Cherry Creek Investment Advisors Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 222.4% during the 1st quarter. Cherry Creek Investment Advisors Inc. now owns 57,556 shares of the company’s stock worth $574,000 after acquiring an additional 39,703 shares during the period. Wesbanco Bank Inc. purchased a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth about $650,000. Finally, Wealth Effects LLC purchased a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth about $150,000. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.